Halozyme Therapeutics, Inc.: Material agreement
Halozyme completed the sale of $1,500.0 million in convertible senior notes due 2033 and funded debt repurchases and capped call transactions.
Neutral newsWhat happened
- Halozyme closed the offering of $1,500.0 million principal amount of 1.50% convertible senior notes due 2033, which included $200.0 million from the initial purchasers exercising their option.
The full interpretation is in the app
Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.
Read the full interpretation